Seoul calls for tighter crypto security after Binance’s US$6b heist | East Asia Tonight Nov 2, 2026

The AI and tech stock market experienced a massive selloff on Friday (October 30, 2026), wiping out more than $1 trillion in market value as investors grew ruthless over massive artificial intelligence spending that has yet to deliver matching profits.<br><br>Intel shares plummeted roughly 28% to 29% in a single day—its worst single-day drop in over 40 to 52 years—after its fourth-quarter revenue guidance missed expectations by about $1.1 billion, erasing over $130–$150 billion in market value.<br><br>• Alphabet (Google): Continued sliding after a 12% drop earlier in the week, pressured by concerns that AI search summaries are cannibalizing core advertising revenue and massive AI capital expenditures pushing free cash flow negative by $9.1 billion.<br><br>• Amazon: Suffered pressure after reporting massive capital expenditure plans ($220+ billion largely for AI infrastructure) that swung its annual free cash flow deeply negative.<br><br>• Semiconductors &amp; Neoclouds: Chips and memory-linked stocks fell sharply, including SanDisk (-13% to -15.8%), AMD, ARM, Qualcomm, and Marvell (down ~10%), alongside AI data center &quot;neocloud&quot; firms like CoreWeave and Nebius (down over 10%).

China has reached parity with the United States in the sheer volume of biomedical research output and early-stage drug pipelines, while the U.S. continues to maintain a lead in research influence, high-impact citations, and cutting-edge breakthrough discoveries.<br><br>Research Volume and Early-Stage Pipelines.<br>• Publication &amp; Output: China has matched or surpassed the U.S. in total scientific publishing and annual biomedical research output, with top institutions in both countries producing roughly 43,500 papers a year, and China accounting for over 32% to 40%+ of global medical research papers.<br><br>• Early-Stage Drug Development: According to data published in JAMA, China&#39;s share of global early-stage drug development programs surged from 8% in 2015 to over 32% by 2024, whereas the U.S. share shifted from 48% down to roughly 37%.<br><br>• Speed &amp; Cost Advantages: Clinical trials and first-in-human studies often move significantly faster and at lower costs in China due to large patient populations and streamlined local processes, prompting a surge in cross-border licensing deals where Western pharma companies license Chinese-developed compounds

Where is the proof that it was done by the North Korean. Was it part of the western propagandas to demonize NK or non aligned countries? Or an easier way to divert attention for their own security weakness?<br><br>As expected SK will be very happy to propagate on the subjects.